250 related articles for article (PubMed ID: 22690083)
41. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
42. Silencing of the thrombomodulin gene in human malignant melanoma.
Furuta J; Kaneda A; Umebayashi Y; Otsuka F; Sugimura T; Ushijima T
Melanoma Res; 2005 Feb; 15(1):15-20. PubMed ID: 15714116
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
44. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
45. The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus.
Wang Y; Hao J; Liu X; Wang H; Zeng X; Yang J; Li L; Kuang X; Zhang T
Lipids Health Dis; 2016 Mar; 15():64. PubMed ID: 27015844
[TBL] [Abstract][Full Text] [Related]
46. Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation: involvement of Sp3 and a methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells.
Wang G; Wei LN; Loh HH
J Biol Chem; 2003 Oct; 278(42):40550-6. PubMed ID: 12890683
[TBL] [Abstract][Full Text] [Related]
47. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
48. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma.
Iwata N; Yamamoto H; Sasaki S; Itoh F; Suzuki H; Kikuchi T; Kaneto H; Iku S; Ozeki I; Karino Y; Satoh T; Toyota J; Satoh M; Endo T; Imai K
Oncogene; 2000 Nov; 19(46):5298-302. PubMed ID: 11077447
[TBL] [Abstract][Full Text] [Related]
49. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
50. Roles of cell division and gene transcription in the methylation of CpG islands.
Bender CM; Gonzalgo ML; Gonzales FA; Nguyen CT; Robertson KD; Jones PA
Mol Cell Biol; 1999 Oct; 19(10):6690-8. PubMed ID: 10490608
[TBL] [Abstract][Full Text] [Related]
51. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
[TBL] [Abstract][Full Text] [Related]
52. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas.
Tchou JC; Lin X; Freije D; Isaacs WB; Brooks JD; Rashid A; De Marzo AM; Kanai Y; Hirohashi S; Nelson WG
Int J Oncol; 2000 Apr; 16(4):663-76. PubMed ID: 10717233
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Bae SI; Lee HS; Kim SH; Kim WH
Br J Cancer; 2002 Jun; 86(12):1888-92. PubMed ID: 12085181
[TBL] [Abstract][Full Text] [Related]
54. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
[TBL] [Abstract][Full Text] [Related]
55. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
Pogribny IP; James SJ
Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
[TBL] [Abstract][Full Text] [Related]
56. Identification of a non-coding KLF4 transcript generated from intron retention and downregulated in human hepatocellular carcinoma.
Zhou J; Lai PB; Tsui SK
Int J Oncol; 2015 Oct; 47(4):1554-62. PubMed ID: 26238073
[TBL] [Abstract][Full Text] [Related]
57. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
58. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
Park WS; Cho YG; Kim CJ; Song JH; Lee YS; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY
Exp Mol Med; 2005 Aug; 37(4):276-81. PubMed ID: 16155404
[TBL] [Abstract][Full Text] [Related]
59. Promoter methylation assay of SASH1 gene in hepatocellular carcinoma.
Peng L; Wei H; Liren L
J BUON; 2014; 19(4):1041-7. PubMed ID: 25536614
[TBL] [Abstract][Full Text] [Related]
60. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Yuan BZ; Durkin ME; Popescu NC
Cancer Genet Cytogenet; 2003 Jan; 140(2):113-7. PubMed ID: 12645648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
